1 week Ago By ABMN Staff
StockNews.com assumed coverage on shares of Pieris Pharmaceuticals ( NASDAQ:PIRS – Free Report ) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Performance PIRS opened at $13.60 on Thursday. The company has a market cap of $17.
95 million, a P/E ratio of -1.12 and a beta of 0.61.
Pieris Pharmaceuticals has a one year low of $6.20 and a one year high of $22.32.
The business’s 50-day simple moving average is $15.65 and its 200-day simple moving average is $14.81.
Institutional Investors Weigh In On Pieris Pharmaceuticals A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC purchased a new stake in Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS – Free Report ) in the 3rd quarter, according to its most recent Form 13F filing with the SEC.
The firm purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for about 0.4% of BML Capital Management LLC’s holdings, making the stock its 21st biggest holding.
BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 40.
11% of the company’s stock. About Pieris Pharmaceuticals Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs.
Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. Read More Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
